2Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end - products expressed in human vascular endothelial cells and perieytes, and their putative roles in diabetes - induced vascular injury. Bio Chem J, 2003,370(3) : 1097 - 1109. 被引量：1
3Wendt TM, Tan Jin, Gu J, et al. RAGE Drives the Development of Glomerulosclerosis and implicates podocyte activation in the pathogensis of diabetic nephropathy. Am J Pathol, 2003, 162 (4) : 1123 - 1137. 被引量：1
4Sakural S, Yonekura H, Yanumaoto Y,et al. The AGE- RAGE system and diabetic nephropathy. J Am Soc Nephrol,2003,14(8 Suppl 3) :S259 - S263. 被引量：1
5Suzuki D, Toyoda M, Yamaoto N, et al. Relationship between the expression of advanced glycation end products(AGE)and the receptor for AGE(RAGE) mRNA in diabetic nephropathy. Intern Med,2006,45(7) :435 - 441. 被引量：1
7Zieman SJ, Kass DA. Advanced glycation end product cross linking in the cardiovascular system: potential therapeutic target for cardiovascular disease. J Drugs, 2004,64 (5) : 459 - 470. 被引量：1
8Schiekofer S, Andrassy M, jiang Chen, et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44MAPK, and nuclear factor kappaB in PBMC. Diabetes, 2003,52 (3) : 621 - 633. 被引量：1
9Goova MT, Li J, Kislir/ger T, et al. Blockade of receptor for advanced glycation products re.stores effective wound healing in diabetic mice. Am.J Pathol,2001,159(2) :513 - 525. 被引量：1
1[1]Neeper M, Schmidt AM, Brett J, et al.Cloning and expression of a cell surface receptor for advanced glycosylation endproducts of protein. J Biol Chem, 1992, 267:14998～15004. 被引量：1
2[2]Schmidt AM, Yan SD, Yan SF, et al.The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta, 2000, 1498:99～111. 被引量：1
3[3]Yeh CH, Sturgis L, Haidacher J, et al.Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-κB transcriptional activation and cytokine secretion. Diabetes, 2001, 50: 1495～1504. 被引量：1
4[4]Vlassara H, Bucala R, Striker L, et al.Pathogenic effects of advanced glycosylation:biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest, 1994, 70: 138～151. 被引量：1
5[5]Hou FF, Reddan DN, Seng WK, et al. Pathogenesis of β2-microglobulin amyloidosis: role of monocytes/macrophages. Semin Dial. 2001, 14: 135～139. 被引量：1
6[6]Sun M, Muinehiro Y, Toshiyuki I, et al.Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat. Int J Exp Path, 1998, 79: 207～222. 被引量：1
7[7]Hou FF, Jiang JP, Guo JQ, et al. Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis. J Am Soc Nephrol, 2002, 13: 1296～1306. 被引量：1
8[8]Higashi T, Sano H, Saishoji T, et al.The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells. Diabetes, 1997, 46: 463～472. 被引量：1
9[9]Hou FF, Miyata T, Boyce J, et al. β2-Microglobulin modified with advanced glycation end products delays monocyte apoptosis. Kidney Int. 2001, 59: 990～1002. 被引量：1
10TANAKA N, YONEKURA H, YAMAGISHI S, et al. The receptor for advanced glycation end-products is induced by the glycation products themselves and TNF-α through NF-kβ and by 17β-estradiol through Sp- 1 in human vascular endothelial cells [ J ]. J Biol Chem, 2000,275: 25781-25790. 被引量：1
2Thompson J, Wilson P, Brandewie K, et al . Renal accumula- tion of biglyean and lipid retention accelerates diabetic ne- phropathy[J]. Am J Pathol, 2011, 179(10):1179d187. 被引量：1
3Davis TM, Ting R, Best JD, et al . Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study[J]. Diabetologia, 2011,54(3) :280 290. 被引量：1
4Ting RD, Keech AC,Drury PL, et al . Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study[J]. Diabetes Care, 2012,35(2) :218 -225. 被引量：1
5Kalani M. The importance of endothelin-1 for mierovascular dysfunction in diabetes[J]. Vase Health Risk Manag , 2008,4 (5):1061 -1068. 被引量：1
